SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after reaching a 52-week high ahead of an expected Q3 report, with traders watching BRIUMVI sales and whether results support the rally. Buyout speculation and possible short covering are also prominent, but the acquisition talk is unconfirmed and some traders attribute the strength to the companys operating momentum instead.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and heavy AI infrastructure spending drove debate, as investors weighed weaker-than-expected results and sharply negative free cash flow against accelerating AWS growth and its outlook. Traders were split between concerns that cash burn and rising investment could pressure the stock and dip-buyers who viewed the initial selloff as overdone; shares rebounded substantially from their lows.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results and strength in parks and streaming have renewed optimism, with traders pointing to analyst upgrades and a potential technical breakout. Others remain skeptical, citing Disneys long-running share-price stagnation and resistance levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels steep drop followed weak forward guidance despite a solid quarter, with traders focused on softer PC demand, manufacturing constraints and analyst downgrades; the pressure also fed into a broader semiconductor and tech selloff. The community is split between calling the reaction excessive and buying the dip, and warning that the outlook and execution problems could prolong the decline.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas prices slide amid mild-weather forecasts that point to weaker heating demand, with surplus inventories adding pressure. Traders are split between buying the decline ahead of winter and expecting further weakness if warm conditions persist; colder forecasts or storage data are seen as potential catalysts for a shift.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the November 14 FDA decision on ivonescimab plus chemotherapy for EGFR-mutated lung cancer, with traders weighing the Phase 3 results and recent positive biliary-cancer data against regulatory concerns, including the lack of statistically significant overall-survival results. Bulls see approval potential and broader promise for the drug, while skeptics stress that the decision remains uncertain and could hinge on FDA concerns about the trial population or manufacturing.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders focusing on the amended upper-limb-function data and recent rare-disease discussions. New commercial-launch job postings and other FDA approvals have fueled optimism about a favorable decision, while skeptics caution that neither hiring nor regulatory flexibility guarantees approval and debate the risk of a CRL; some also attribute price swings to short covering or rumors of a leak.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL combination drew attention after Phase 2 NEOASIS data at ESMO showed strong pathologic responses in a small dMMR colon cancer cohort, alongside discussion of sarcoma results. Traders called the findings encouraging but debated their significance given the small, early-stage studies and awaited Phase 3 confirmation, while some questioned why the share price weakened despite the data and raised dilution and execution concerns.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,155,828.93500734 in circulation. The last known price of Hedera is 0.07221819 USD and is up 4.74 over the last 24 hours. It is currently trading on 465 active market(s) with $92,347,671.42 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBARs sharp rally and elevated volume are being linked by traders to IBM-related cloud news and Hederas reported connections to NVIDIAs AI safety platform. Enthusiasm over enterprise and AI use cases is tempered by profit-taking and skepticism that the announcements will translate into meaningful adoption or token demand.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report and narrower 2026 production guidance are driving the selloff, with traders focusing on weaker results and production setbacks, including at Cigar Lake. Some see the report as disappointing and the stock as overvalued, while long-term bulls point to firm uranium prices and nuclear demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Alert: Omada Health CEO Sean Duffy Sells 31,457 Shares

Key PointsTraded 31,457 shares with a transaction value of ~$735,150 based on a weighted average price of $23.37 per share...

Here's Why Teladoc's Integrated Care Business Deserves More Attention

TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.

Omada Health (OMDA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Is Hinge Health Stock a Buy as Growth Accelerates and Risks Rise?

HNGE's rapid revenue growth, widening margins and higher 2026 outlook strengthen its case, but expansion raises execution risks.

Hinge Health's Cylinder Deal Opens a $135B GI Care Growth Opportunity

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

HNGE Rallies 64.6% in 3 Months as Growth and Margins Gain Momentum

Hinge Health 64.6% three-month rally is backed by surging revenues, wider margins and a raised 2026 outlook, but execution expectations are rising.

Omada Health, Inc. (OMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Omada Health, Inc. (OMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Omada Health, Inc. (OMDA) Q2 Earnings and Revenues Top Estimates

Omada Health, Inc. (OMDA) delivered earnings and revenue surprises of +200.00% and +8.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Omada Health Reaches Analyst Target Price

In recent trading, shares of Omada Health Inc (Symbol: OMDA) have crossed above the average analyst 12-month target price of $23.33, changing hands for $23.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on val...

Omada Health, Inc. (OMDA) Is Up 7.18% in One Week: What You Should Know 

Does Omada Health, Inc. (OMDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Omada Health, Inc. engages in the provision of digital health services. It offers online diabetes and obesity prevention programs, health coaching, and integration of web, mobile, and smart devices. The company was founded by Andrew DiMichele, Adrian James, and Sean Duffy in 2011 and is headquartered in South San Francisco, CA.

Omada Health Inc.

Omada Health Stock Jumps Into Retail Focus As Wall Street Lifts Price Targets After ‘Beat And Raise’ Quarter, GLP-1 Push

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Morgan Stanley, Evercore ISI, and Barclays raised price targets to between $28–$32, citing Omada’s revenue growth and its first positive adjusted EBITDA.</li><li>The company plans to integrate GLP-1 prescribing and medication management into its weight-health program, expanding its digital-care platform.</li><li>Retail traders highlighted the company’s strong balance sheet, high gross margins, and operating leverage as signs of growth potential.</li></ul><p>Retail chatter on Omada Health surged over the weekend after several brokerages raised price targets following stronger-than-expected third-quarter (Q3) results and the company’s new GLP-1 prescribing initiative for its weight-health program.</p><h2 class="st-heading-2"><strong>Analyst Upgrades</strong></h2><p>Morgan Stanley raised its price target on Omada Health to $32 from $30 and kept an ‘Overweight’ rating, citing 49% year-over-year revenue growth, an 11% beat versus consensus, and the company’s first quarter of positive adjusted EBITDA. The firm said momentum continues and highlighted the addition of GLP-1 prescribing to Omada’s offering as a key development.</p><p>Evercore ISI increased its price target to $28 from $27 and maintained an ‘Outperform’ rating, noting that Q3 revenue and EBITDA beat expectations and full-year 2025 guidance was raised.</p><p>Barclays lifted its price target to $29 from $28 and reiterated an ‘Overweight’ rating, describing Omada’s results as “another beat and raise quarter.”</p><h2 class="st-heading-2"><strong>Q3 Review</strong></h2><p>Omada reported revenue of $68 million, ahead of consensus estimates of $61.2 million. Total members rose 53% to 831,000, while the company’s net loss narrowed to $3 million from $9 million a year earlier. Omada achieved its first positive adjusted EBITDA of $2 million, compared with a $5 million loss in the prior-year period.</p><p>Gross margin improved to 66%, and cash and cash equivalents totaled $199 million at quarter-end.</p><p>CEO Sean Duffy said the results demonstrate “the strength of Omada’s multi-product platform” as the company deepens its innovation in GLP-1 care options and AI tools aimed at delivering “sustainable outcomes” and “cost savings” for customers.</p><h2 class="st-heading-2"><strong>GLP-1 Expansion And Product Updates</strong></h2><p>The company announced plans to integrate prescribing and medication management for anti-obesity medications, including GLP-1s, into its weight-health program.</p><p>Omada also launched Meal Map, an AI-driven nutrition platform that prioritizes nutrient quality over calorie tracking, and published results from its 30th peer-reviewed research study, which showed savings generated from its Joint &amp; Muscle Health program. Additional results showed that members largely sustained their weight a year after stopping GLP-1 treatment.</p><h2 class="st-heading-2"><strong>Financial Outlook</strong></h2><p>Omada raised its FY25 revenue guidance to $251.5 million-$254.5 million, up from a prior range of $235 million–$241 million, and now expects adjusted EBITDA between breakeven and a $2 million loss, compared with earlier guidance for a $9 million–$5 million loss.</p><h2 class="st-heading-2"><strong>Stocktwits Traders Say Omada’s GLP-1 Plan Shows Real Execution</strong></h2><p>On Stocktwits, retail sentiment for Omada was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:963/138;" src="https://news.stocktwits-cdn.com/omda_ss_jpg_d120b63835.webp" alt="omda ss.jpg" width="963" height="138"><figcaption>OMDA sentiment and message volume as of November 9 | Source: Stocktwits</figcaption></figure><p>One user said some companies “just mention GLP-1 to garner headlines” without clear execution plans, but noted that Omada Health already has case studies, proof-of-concept, and “the balance sheet to boost this up.” They added that the business model is proven and now depends on strong marketing to capture the opportunity.</p><p><stembedurl>https://stocktwits.com/Jasooon/message/635551904</stembedurl></p><p>Another user said the company’s financials “prove it,” pointing to high gross margins, positive adjusted EBITDA, and improved cash flow as signs of operating leverage and a “stellar management team.”</p><p><stembedurl>https://stocktwits.com/Jasooon/message/635551456</stembedurl></p><p><a href="https://stocktwits.com/symbol/OMDA">Omada Health’s stock</a> has declined 12% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Omada Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Morgan Stanley, Evercore ISI, and Barclays raised price targets to between $28–$32, citing Omada’s revenue growth and its first positive adjusted EBITDA.

Omada Health, Inc.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.73
Prev Close	$19.65
Open	$19.35
Dividend Yield	0.00%
50-Day Moving Average	$20.75
Beta	0.97
Avg. Volume	1.51M
PE Ratio	284.65

52-Week High	$26.13
52-Week Low	$10.28
Market Capitalization	$1.15B
EPS (Annual)	-$0.2187
Price to Book	4.49
Revenue Per Employee	$284,072.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

OMDA Fundamentals